A Multicenter, Open-label, Pilot Study of TAK-935 in patients with 15q duplication syndrom or CDKL5 deficiency disorder.
A clinical trial for children with 15Q duplication syndrome or CDKL5 deficiency disorder to help control seizures.
Sponsor: Ovid Therapeutics, Inc.
Enrolling: Male and Female Patients
Study Length: 22 Weeks
Clinic Visits: 8
IRB Number: AAAS1026
U.S. Govt. ID: NCT03694275
Contact: Joanne Carroll: 212-305-5508 / jc688@cumc.columbia.edu
Additional Study Information: The purpose of this research is to determine whether a new investigational drug called TAK-935 is safe and whether it may help treat epilepsy in children with 15q duplication syndrome or CDKL5 deficiency disorder.
This study is closed
Wendy Chung, MD, PhD
Do You Qualify?
Has your child been diagnosed with 15q duplication syndrome, or CDKL5 deficiency disorder? Yes No
Has your child had 3 or more seizures within the last 3 months? Yes No
Have there been any anti-epileptic medication changes within the last 4 weeks? Yes No
Does your child weigh 22 lbs or more? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Joanne Carroll